Discovery of new S-adenosylmethionine decarboxylase inhibitors for the treatment of Human African Trypanosomiasis (HAT)

Drug and Biomaterial R&D, Genzyme Corporation, Waltham, MA 02451, United States.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.42). 07/2009; 19(11):2916-9. DOI: 10.1016/j.bmcl.2009.04.096
Source: PubMed


Modification of the structure of trypanosomal AdoMetDC inhibitor 1 (MDL73811) resulted in the identification of a new inhibitor 7a, which features a methyl substituent at the 8-position. Compound 7a exhibits improved potencies against both the trypanosomal AdoMetDC enzyme and parasites, and better blood brain barrier penetration than 1.

Download full-text


Available from: Robert H Barker, Nov 19, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The protozoan parasites Trypanosoma brucei and Trypanosoma cruzi are the causative agents of African trypanosomiasis and Chagas disease, respectively. These are debilitating infections that exert a considerable health burden on some of the poorest people on the planet. Treatment of trypanosome infections is dependent on a small number of drugs that have limited efficacy and can cause severe side effects. Here, we review the properties of these drugs and describe new findings on their modes of action and the mechanisms by which resistance can arise. We further outline how a greater understanding of parasite biology is being exploited in the search for novel chemotherapeutic agents. This effort is being facilitated by new research networks that involve academic and biotechnology/pharmaceutical organisations, supported by public-private partnerships, and are bringing a new dynamism and purpose to the search for trypanocidal agents.
    Expert Reviews in Molecular Medicine 10/2009; 11:e31. DOI:10.1017/S1462399409001252 · 5.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
    ChemInform 10/2009; 40(42). DOI:10.1002/chin.200942196
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter provides an outline of the recent advances made in drug discovery for neglected tropical diseases caused by infective kinetoplastid parasites. There has been resurgence in interest in the discovery and development of new treatments for neglected diseases in the past several years. In particular, diseases caused by kinetoplastid parasites have received considerable attention. In addition, screening for the parasiticidal activity of compounds has frequently been performed simultaneously against representative strains of the three major parasites— Trypanosoma brucei spp., Leishmania spp., and Trypanosoma cruzi—hence, many of the chemotypes described in the chapter exhibit activity against all three. Most efforts continue to rely on the initial evaluation of compounds in whole-cell parasiticidal assays, but approaches based on specific biochemical targets and pathways have increasingly been reported due to the availability of the complete genome of these parasites and the subsequent understanding afforded by this knowledge. Several new clinical and preclinical candidates have been progressed that target each parasite, but continued efforts are required to have significant impact on these devastating diseases.
    Annual reports in medicinal chemistry 12/2010; 45:277-294. DOI:10.1016/S0065-7743(10)45017-4 · 1.36 Impact Factor
Show more